July 16, 2011 -- Novartis may IPO on the Shanghai stock exchange, which expects to open an international section for foreign multinationals by the end of 2012; Shanghai Pharma plans to make a $310 million investment to, among other things, solidify its drug distribution business in North China; Guizhou Bailing Group Pharma paid $6.2 million for a 60% stake in TCM-maker Guizhou Herentang Pharma; Sagent Pharma of the US will add Chongqing Lummy Pharma to its long list of China collaborators; Hikma Pharma, a Jordanian drugmaker, paid $5 million to acquire a significant minority interest in Hubei Haosun Pharma; Bimeda Animal Health, a Irish veterinary medicine company, announced a China joint venture with Shijiazhuang Rainbow Labs; China continues to outpace India in academic patents and research; Bristol-Myers Squibb expects China to become its second or third largest market within a decade; and 3SBio was granted SFDA approval for its high-dose formulation of EPIAO, an anemia treatment. More details….
Stock Symbols: (NYSE: NVS) (SHA: 601607) (SHE: 002424) (NSDQ: SGNT) (SHE: 300006) (NYSE: BMY) (NSDQ: SSRX)
